The metabolic syndrome in Australia : prevalence using four definitions

Cameron, Adrian J., Magliano, Dianna J., Zimmet, Paul Z., Welborn, Tim and Shaw, Jonathan E. 2007, The metabolic syndrome in Australia : prevalence using four definitions, Diabetes research and clinical practice, vol. 77, no. 3, pp. 471-478.

Attached Files
Name Description MIMEType Size Downloads

Title The metabolic syndrome in Australia : prevalence using four definitions
Author(s) Cameron, Adrian J.
Magliano, Dianna J.
Zimmet, Paul Z.
Welborn, Tim
Shaw, Jonathan E.
Journal name Diabetes research and clinical practice
Volume number 77
Issue number 3
Start page 471
End page 478
Publisher Elsevier Science Publishers B.V.
Place of publication Amsterdam, The Netherlands
Publication date 2007-09
ISSN 0168-8227
1872-8227
Keyword(s) metabolic syndrome
Australia
insulin resistance
cardiovascular disease risk
central obesity
AusDiab
Summary Objective : To compare the prevalence of the Metabolic Syndrome (MetS) defined by four definitions and to determine which definition best identifies those at high cardiovascular disease (CVD) risk and with insulin resistance.

Methods : AusDiab is a population-based survey of 11,247 Australians. Participants had anthropometry, blood pressure, and fasting biochemistry. Ten-year CVD risk was calculated.

Results :
The prevalence of the MetS using the ATPIII, WHO, IDF, and EGIR definitions was 22.1% (95%Cl: 18.8, 25.4), 21.7% (19.0, 24.3), 30.7% (27.1, 34.3), and 13.4% (11.8, 14.9), respectively. Comparing those with to those without the MetS, the odds ratios (95%CI) for having a 10 year CVD risk ≥15% were 6.6 (5.4, 8.2), 5.5 (4.7, 6.5), 5.6 (4.8, 6.6), and 3.5 (3.0, 4.1), for the WHO, ATPIII, IDF, and EGIR definitions, respectively. The population attributable risk (PAR) of high CVD risk due to the MetS was highest for the IDF (23.4%). Insulin resistance was detected in 56.1, 69.7, 50.9, and 91.1% of those meeting the ATPIII, WHO, IDF, and EGIR definitions, respectively.

Conclusion :
The WHO definition was associated with the greatest CVD risk, but is not practical for clinical use. The higher PAR due to the IDF definition, with only slightly lower CVD risk than WHO, and clinical utility of the IDF definition, indicates that it may be a useful tool for CVD prevention.
Language eng
Field of Research 111706 Epidemiology
Socio Economic Objective 920104 Diabetes
HERDC Research category C1.1 Refereed article in a scholarly journal
Copyright notice ©2007, Elsevier Ireland Ltd.
Persistent URL http://hdl.handle.net/10536/DRO/DU:30021312

Connect to link resolver
 
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 41 times in TR Web of Science
Scopus Citation Count Cited 51 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 540 Abstract Views, 0 File Downloads  -  Detailed Statistics
Created: Fri, 11 Dec 2009, 10:07:22 EST by Adrian Cameron

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact drosupport@deakin.edu.au.